Class: Oral multikinase inhibitor (tyrosine kinase inhibitor, TKI).

Indications in sarcoma/related tumors:

Mechanism of Action:

Dosing (adult):

  • 160 mg PO once daily (with a low-fat meal), for 3 weeks on / 1 week off (28-day cycle).
  • Tablets = 40 mg → usually 4 tablets daily.
  • Dose reductions: 120 mg → 80 mg if toxicity.

Key Toxicities (pharmacist needs to know):

  • Hand-foot skin reaction (HFSR) (most distinctive, dose-limiting).
  • Hepatotoxicity (can be severe/fatal, monitor closely).
  • Hypertension.
  • Fatigue, diarrhea, mucositis.
  • Voice changes (dysphonia, common but benign).
  • Rare: hemorrhage, cardiac ischemia.

Monitoring:

  • LFTs: baseline, then every 2 weeks for first 2 months, monthly thereafter.
  • BP: baseline and weekly early in therapy, then periodically.
  • Skin/toxicity checks for HFSR — intervene early with emollients, urea-based creams, dose modifications.
  • CBC, electrolytes as indicated.
  • Watch for drug–drug interactions (CYP3A4 substrate; avoid strong inhibitors/inducers).

Pharmacist Pearls:

  • Take with low-fat meal (high-fat meals ↑ exposure and toxicity).
  • Counsel patients to report palmar-plantar skin changes, jaundice, dark urine, uncontrolled HTN.
  • Dose interruptions and reductions are common for toxicity management.
  • Hand-foot skin reaction prevention: prophylactic moisturizers, avoid friction/pressure, consider keratolytics.
  • Patient adherence critical (oral therapy).

Take-home for BPS prep:

Regorafenib is an oral TKI used in GIST after imatinib & sunitinib. Pharmacists must monitor liver function, blood pressure, and skin toxicity (HFSR), and reinforce adherence and food instructions (low-fat meals).